Pharmacist review prevents evolving metformin-associated lactic acidosis

Journal of Clinical Pharmacy and Therapeutics

Volumn 39, Issue 5, 2014, Pages 567-570

  Naunton, M ^a   Kyle, G ^a   Owoka, F ^a   Naunton Boom, K ^a  

^a UNIVERSITY OF CANBERRA   (Australia)

Author keywords

diabetes; lactic acidosis; metformin; pharmacist

Indexed keywords

ATORVASTATIN; BETAHISTINE; BICARBONATE; DILTIAZEM; DILTIAZEM SR; DOMPERIDONE; FENTANYL; FERROUS FUMARATE; FOLIC ACID; GLICLAZIDE; LACTIC ACID; METFORMIN PLUS SITAGLIPTIN; MIRTAZAPINE; PRAZOSIN; RAMIPRIL; REBOXETINE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; METFORMIN;

AGED; CASE REPORT; DRUG MEGADOSE; DRUG WITHDRAWAL; EMERGENCY WARD; HOME MEDICINES REVIEW; HUMAN; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; MALE; MEDICATION THERAPY MANAGEMENT; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACEUTICAL CARE; PHARMACIST; REVIEW; SYSTEMATIC REVIEW (TOPIC); VOMITING; ACIDOSIS, LACTIC; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; PHARMACY;

ACIDOSIS, LACTIC; AGED; COMMUNITY PHARMACY SERVICES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; LACTIC ACID; MALE; METFORMIN;

EID: 84929131734     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12187     Document Type: Review

References (28)

1. Lu WR, Defilippi J, Braun A,. Unleash metformin reconsideration of the contraindication in patients with renal impairment. Ann Pharmacother, 2013; 47: 1488-1497.
2. Renda F, Mura P, Finco G, Ferrazin F, Pani L, Landoni G,. Metformin-associated lactic acidosis requiring hospitalization. A national 10 year survey and a systematic literature review. Eur Rev Med Pharmacol Sci, 2013; 17: 45-49.
3. Huang W, Castelino RL, Peterson GM,. Metformin usage in type 2 diabetes mellitus: are safety guidelines adhered to? Intern Med J, 2014; 44: 266-272.
4. DeFronzo RA,. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med, 1999; 131: 281-303.
5. Soyoral YU, Begenik H, Emre H, Aytemiz E, Ozturk M, Erkoc R,. Dialysis therapy for lactic acidosis caused by metformin intoxication: presentation of two cases. Hum Exp Toxicol, 2011; 30: 1995-1997.
6. Katsilambros N, Kanaka-Gantenbein C, Liatis S, Makrilakis K, Tentolouris N,. Lactic acidosis in diabetes. In: Diabetic emergencies: diagnosis and clinical management. Oxford: Wiley-Blackwell, 2011.
7. Vecchio S, Giampreti A, Petrolini VM, et al,. Metformin accumulation: lactic acidosis and high plasmatic metformin levels in a retrospective case series of 66 patients on chronic therapy. Clin Toxicol, 2014; 52: 129-135.
8. Salpeter S, Greyber E, Pasternak G, Salpeter EE,. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev, 2010; 1: 1-233.
9. Lalau JD, Race JM,. Metformin and lactic acidosis in diabetic humans. Diabetes Obes Metab, 2000; 2: 131-137.
10. van Berlo-van de Laar IRF, Vermeij CG, Doorenbos CJ,. Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements. J Clin Pharm Ther, 2011; 36: 376-382.
11. Juurlink DN, Roberts DM,. The enigma of metformin-associated lactic acidosis. Clin Toxicol (Philadelphia, Pa), 2014; 52: 85-87.
12. Kwong SC, Brubacher J,. Phenformin and lactic acidosis: a case report and review. J Emerg Med, 1998; 16: 881-886.
13. Hamnvik OPR, McMahon GT,. Balancing risk and benefit with oral hypoglycemic drugs. Mt Sinai J Med, 2009; 76: 234-243.
14. Scott KA, Martin JH, Inder WJ,. Acidosis in the hospital setting: is metformin a common precipitant? Inter Med J, 2010; 40: 342-346.
15. Gorter KJ, van de Laar FA, Janssen PG, Houweling ST, Rutten GE,. Diabetes: glycaemic control in type 2 (drug treatments). Clin Evid, 2012; 10: 609.
16. Rachoin JS, Weisberg LS, McFadden CB,. Treatment of lactic acidosis: appropriate confusion. J Hosp Med, 2010; 5: E1-E7.
17. Naranjo CA, Busto U, Sellers EM, et al,. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther, 1981; 30: 239-245.
18. Carter SR, Chen TF, White L,. Home medicines reviews: a quantitative study of the views of recipients and eligible non-recipients. Int J Pharm Pract, 2012; 20: 209-217.
19. Castelino RL, Bajorek BV, Chen TF,. Are interventions recommended by pharmacists during Home Medicines Review evidence-based? J Eval Clin Pract, 2011; 17: 104-110.
20. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA,. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med, 1998; 338: 265-266.
21. eTherapeutic Guidelines. Endocrinology: Type 2 diabetes management, antihyperglycaemic therapy-metformin 2014 [cited 2014. Available at: http://online.tg.org.au.ezproxy1.canberra.edu.au/ip/desktop/index.htm.(accessed 12 April 2014).
22. NICE. Type 2 Diabetes: The Management of Type 2 Diabetes 1999 [cited 2014. Available at: http://www.nice.org.uk/nicemedia/live/12165/44320/44320.pdf (accessed 12 April 2014).
23. Nye HJ, Herrington WG,. Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract, 2011; 118: c380-c383.
24. Australian Medicine Handbook. Endocrine drugs: Drugs for diabetes-metformin. Adelaide: Australian Medicines Handbook Pty Ltd, 2014.
25. Alphapharm Pty Ltd. Metformin hydrochloride Product Information. 2012; Available at: http://online.tg.org.au.ezproxy1.canberra.edu.au/ip/desktop/index. htm. (accessed 12 April 2014).
26. Kajbaf F, Arnouts P, de Broe M, Lalau J-D,. Metformin therapy and kidney disease: a review of guidelines and proposals for metformin withdrawal around the world. Pharmacoepidemiol Drug Saf, 2013; 22: 1027-1035.
27. Lalau J-D, Arnouts P, Sharif A, De Broe ME,. Metformin and other antidiabetic agents in renal failure patients. Kidney Int, 2014. doi: 10.1038/ki.2014.19. [Epub ahead of print].
28. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW,. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008; 359: 1577-1589.